| Liang, Xinjun |
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer |
|
|
| Recruiting | 3 | 560 | RoW | Irinotecan Hydrochloride Injection, HX008, Placebo | Taizhou Hanzhong biomedical co. LTD | Stomach Cancer | 08/23 | 08/23 | | |
NCT04385550: A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma |
|
|
| Not yet recruiting | 3 | 528 | RoW | Anlotinib hydrochloride capsule, AK105 injection, Paclitaxel injection, Docetaxel injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma | 10/23 | 12/23 | | |
| Recruiting | 3 | 400 | Europe, Canada, Japan, US, RoW | tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil | Seagen Inc., Merck Sharp & Dohme LLC | Colorectal Neoplasms | 08/25 | 04/28 | | |
NCT05652894: A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 3 | 190 | RoW | HX008, Investigator's Choice Chemotherapy | Taizhou Hanzhong biomedical co. LTD | Metastatic Colorectal Cancer | 01/26 | 10/28 | | |
NCT05180734: PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer |
|
|
| Active, not recruiting | 3 | 878 | RoW | JS001/Placebo, Postoperative Adjuvant Chemotherapy, JS001/placebo combine with Postoperative Adjuvant Chemotherapy | Shanghai Junshi Bioscience Co., Ltd. | Gastric or Esophagogastric Junction Adenocarcinoma | 06/26 | 07/28 | | |
NCT05188209: A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Advanced Gastric Cancer. |
|
|
| Recruiting | 2 | 60 | RoW | MRG003 | Shanghai Miracogen Inc. | Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Gastroesophageal Junction Carcinoma | 03/23 | 08/23 | | |
| Recruiting | 1/2 | 364 | RoW | SHR-A1811 combined with Pyrotinib., SHR-A1811 combined with other antitumor therapies | Jiangsu HengRui Medicine Co., Ltd. | HER2-expressing Advanced Solid Tumors | 11/26 | 12/26 | | |
NCT04755543: A Study of LP002 for the Treatment of Patients With Malignant Digestive System Neoplasms |
|
|
| Recruiting | 1 | 94 | RoW | LP002, Cisplatin, Fluorouracil, OH2 oncolytic virus | Taizhou HoudeAoke Biomedical Co., Ltd. | Digestive System Neoplasms | 06/21 | 06/22 | | |
| Recruiting | 1 | 189 | RoW | KY-0118 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd. | Neoplasms, Neoplasms by Histologic Type | 12/25 | 12/25 | | |
NCT04257110: A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors |
|
|
| Active, not recruiting | 1 | 208 | US, RoW | BB-1701 | Bliss Biopharmaceutical (Hangzhou) Co., Ltd | Locally Advanced/Metastatic HER2 Positive Solid Tumors | 08/24 | 12/24 | | |
NCT06761651: A Study of TAVO412 in Patients with Cancer (TAVO412) |
|
|
| Recruiting | 1 | 50 | RoW | TAVO412 | Tavotek Biotherapeutics | Cancer | 01/26 | 10/26 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
|
CIBI343A101, NCT05458219: A First-in-human Study of IBI343 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 470 | US, RoW | IBI343 | Innovent Biologics (Suzhou) Co. Ltd., Innovent Biologics, Inc., TigerMed | Locally Advanced Unresectable or Metastatic Solid Tumors | 12/25 | 12/25 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
| Recruiting | 1 | 156 | RoW | ATG-022 | Antengene Biologics Limited | Advanced/Metastatic Solid Tumors | 06/26 | 06/26 | | |
NCT06712524: Effect of Different Surgical Approaches of Granulomatous Mastitis |
|
|
| Recruiting | N/A | 240 | RoW | Breast-conserving plastic surgery, Traditional breast surgery | Hubei Cancer Hospital | Breast-conserving Plastic Surgery, Granulomatous Mastitis | 12/27 | 12/27 | | |
